Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Conference Call: Insights and Impacts
On March 26, 2025, at 4:30 PM ET, Fortress Biotech, Inc. (FBIO) held its Q4 2024 earnings conference call. The call was led by Jaclyn Jaffe, Senior Director of Corporate Operations, Claude Maraoui, Co-Founder, President, and CEO, Joseph Benesch, CFO, Srinivas Sidgiddi, VP of R&D, and Louis Donati, Director of Market Access. Participating as analysts were Thomas Flaten from Lake Street Capital Markets, Scott Henry from AGP, Brandon Folkes from Rodman & Renshaw, and Jason Wittes from ROTH Capital, with Kalpit Patel from B. Riley Securities acting as the call operator.
Company Overview
Fortress Biotech, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative technologies and therapeutics. The company’s primary focus is oncology, with a diverse portfolio of 20+ assets in various stages of development. Fortress Biotech’s mission is to deliver transformative therapies to patients with unmet medical needs.
Q4 2024 Earnings and Financial Performance
During the call, the company reported Q4 2024 revenue of $17.5 million, a 35% increase from the previous year. Net loss for the quarter was reported at $16.1 million, compared to a net loss of $13.2 million in Q4 2023. The increase in revenue was primarily driven by the successful launch of new products and the acquisition of new assets. The net loss was attributed to increased R&D and SG&A expenses.
Pipeline and Product Updates
The call highlighted several pipeline and product updates. The most notable was the progress of 1450, a novel, orally administered, small molecule inhibitor of the androgen receptor. The company announced positive results from a Phase 2 clinical trial, demonstrating significant reductions in prostate-specific antigen (PSA) levels. Fortress Biotech plans to initiate a Phase 3 trial in H2 2025.
Additionally, the company provided updates on its other assets, including a Phase 3 trial for Rubraca in ovarian cancer, a Phase 2 trial for CPI-613 in pancreatic cancer, and a Phase 2 trial for Toripalimab in gastric cancer. The company also announced plans to initiate a Phase 1 trial for a new asset in H1 2026.
Impact on Investors
Following the earnings call, Fortress Biotech’s stock price saw a significant increase, up by over 10% in after-hours trading. This was due to the positive financial performance and promising pipeline updates reported during the call.
Impact on the World
The progress of Fortress Biotech’s pipeline has the potential to significantly impact the world of oncology. With a focus on developing transformative therapies for unmet medical needs, the company’s successes could lead to improved treatment options and outcomes for patients with various types of cancer.
Conclusion
Fortress Biotech’s Q4 2024 earnings conference call provided valuable insights into the company’s financial performance and pipeline progress. The positive financial results and promising pipeline updates were met with enthusiasm from investors, resulting in a significant increase in stock price. The potential impact of Fortress Biotech’s work on the world of oncology is significant, with the potential to deliver transformative therapies to patients in need.
- Fortress Biotech reported Q4 2024 revenue of $17.5 million, a 35% increase from the previous year
- Net loss for the quarter was reported at $16.1 million, compared to a net loss of $13.2 million in Q4 2023
- Positive results from a Phase 2 clinical trial of 1450 in the treatment of prostate cancer
- Plans to initiate a Phase 3 trial for 1450 in H2 2025
- Positive investor reaction, with a significant increase in stock price following the conference call
- Potential impact on the world of oncology with the development of transformative therapies for unmet medical needs
